文献速递疼痛医学术前评估与围术期医学

美国阿片危机:联邦与州法律问题综述

The US Opioid Crisis: Current Federal and State Legal Issues.
PubMed 文献 · Anesth Analg · 2017-01-01

美国阿片滥用危机每年导致超过33,000例死亡,其中约半数归因于处方阿片。联邦机构(CDC、FDA、DEA、司法部)与州政府各自承担监管、执法与公共卫生职责,州级PDMP、纳洛酮可及性立法及对药企诉讼是当前法律应对的核心手段。

要点

  • CDC 2016年发布慢性疼痛阿片处方指南,试图规范处方行为。
  • DEA与司法部可起诉非法处方的医生与“药丸工厂”。
  • 州政府可强制医师注册使用PDMP并推动纳洛酮无处方获取。

核心结论

  • 美国阿片滥用危机每年导致超过33,000例死亡,其中约半数为处方阿片所致。
  • 联邦与州政府已通过指南、执法、监测和诉讼等多重法律手段介入阿片危机。

研究设计与样本

  • 本文为综述,梳理美国联邦与州层面应对阿片危机的法律与监管措施。

主要发现

  • CDC于2016年发布慢性疼痛阿片处方指南,旨在控制和规范阿片处方。
  • DEA与司法部拥有执法权,可起诉药丸工厂和非法处方的医生。
  • FDA有权批准更安全的即释和长效阿片制剂,也可要求药企停止生产某药物。
  • 几乎每个州都已某种程度实施PDMP,但需强制使用并加强州际信息共享以提升效果。
  • 部分州立法允许无处方获取纳洛酮,使急救人员、患者和家属可获得救命药物。

关键数值与推荐

  • CDC 2016年《慢性疼痛阿片处方指南》用于控制和规范阿片处方。
  • DEA可推动在州级管理的PDMP使用,并对II类和III类管制药物实行电子处方。
  • 州可将医师执照与注册并使用PDMP挂钩,作为处方管制药物的条件。

临床怎么用

  • 麻醉科医生应关注联邦与州阿片处方法规对围术期镇痛处方行为的影响。
  • 了解PDMP使用要求和纳洛酮可及性立法,有助于优化术后疼痛管理与安全。

局限性

  • 本文为法律与监管综述,未报告原始研究数据、样本量或统计检验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The United States is in the midst of a devastating opioid misuse epidemic leading to over 33,000 deaths per year from both prescription and illegal opioids. Roughly half of these deaths are attributable to prescription opioids. Federal and state governments have only recently begun to grasp the magnitude of this public health crisis. In 2016, the Centers for Disease Control and Prevention released their Guidelines for Prescribing Opioids for Chronic Pain. While not comprehensive in scope, these guidelines attempt to control and regulate opioid prescribing. Other federal agencies involved with the federal regulatory effort include the Food and Drug Administration (FDA), the Drug Enforcement Agency (DEA), and the Department of Justice. Each federal agency has a unique role in helping to stem the burgeoning opioid misuse epidemic. The DEA, working with the Department of Justice, has enforcement power to prosecute pill mills and physicians for illegal prescribing. The DEA could also implement use of prescription drug monitoring programs (PDMPs), currently administered at the state level, and use of electronic prescribing for schedule II and III medications. The FDA has authority to approve new and safer formulations of immediate- and long-acting opioid medications. More importantly, the FDA can also ask pharmaceutical companies to cease manufacturing a drug. Additionally, state agencies play a critical role in reducing overdose deaths, protecting the public safety, and promoting the medically appropriate treatment of pain. One of the states' primary roles is the regulation of practice of medicine and the insurance industry within their borders. Utilizing this authority, states can both educate physicians about the dangers of opioids and make physician licensure dependent on registering and using PDMPs when prescribing controlled substances. Almost every state has implemented a PDMP to some degree; however, in addition to mandating their use, increased interstate sharing of prescription information would greatly improve PDMPs' effectiveness. Further, states have the flexibility to promote innovative interventions to reduce harm such as legislation allowing naloxone access without a prescription. While relatively new, these types of laws have allowed first responders, patients, and families access to a lifesaving drug. Finally, states are at the forefront of litigation against pharmaceutical manufacturers. This approach is described as analogous to the initial steps in fighting tobacco companies. In addition to fighting for dollars to support drug treatment programs and education efforts, states are pursuing these lawsuits as a means of holding pharmaceutical companies accountable for misleading marketing of a dangerous product.

来源:Anesth Analg,查看原文。版权归原作者所有。

引用

  1. Soelberg CD, Brown RE, Du Vivier D, et al. The US Opioid Crisis: Current Federal and State Legal Issues. Anesth Analg. 2017. PMID: 29049113. doi:10.1213/ANE.0000000000002403

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。